Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
Status:
Unknown status
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label,multicenter Phase II study for evaluating the efficacy and
safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy as neoadjuvant treatment in
HER2 positive early stage or locally advanced breast cancer.